Bisphosphonates as antimyeloma drugs
| Autor: | N D Modi, Suzanne Lentzsch |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
medicine.medical_treatment Review survival Bone resorption zoledronic acid Bone Marrow medicine Humans Immunologic Factors In patient bisphosphonates Multiple myeloma Diphosphonates Myeloma cell business.industry Hematology Bisphosphonate medicine.disease Pathophysiology multiple myeloma pamidronate medicine.anatomical_structure Oncology Immunology Cancer research Bone marrow business |
| Zdroj: | Leukemia |
| ISSN: | 1476-5551 0887-6924 |
| DOI: | 10.1038/leu.2011.282 |
| Popis: | In patients with symptomatic multiple myeloma (MM), bisphosphonate (BP) treatment has been widely used to prevent bone loss and preserve skeletal health because of its proven effects on inhibiting osteoclast-mediated bone resorption. In addition to their effects on osteoclasts, it is becoming increasingly evident that BPs may have additional effects on the bone microenvironment and cells other than osteoclasts that may potentially inhibit the development and progression of MM. This review focuses on the pathophysiology of MM with an emphasis on the events that drive MM progression within the bone and the mechanisms by which BPs may inhibit specific processes. The underlying molecular mechanisms that drive the modulation of cellular fate and function and consequent physiological outcomes are described. Direct effects on myeloma cell growth and survival and the interactions between myeloma cells and the bone microenvironment are discussed. Clinical evidence of the antimyeloma effects of BPs is emerging and is also reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|